Amid initial public and scientific optimism for hydroxychloroquine (HCQ) as a potential treatment for COVID-19, health care professionals raised concerns about shortages of this inexpensive drug, which is widely used in the treatment of several rheumatic diseases such as arthritis. A new national survey of rheumatologists led by researchers at the McGill University Health Centre (MUHC) shows that most of them reported difficulties accessing or renewing the drug.